174 related articles for article (PubMed ID: 36680260)
1. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals.
Leal C; Strogoff-de-Matos J; Theodoro C; Teixeira R; Perez R; Guaraná T; de Tarso Pinto P; Guimarães T; Artimos S
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680260
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
3. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
4. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Tabu K; Mawatari S; Oda K; Kumagai K; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Fujisaki K; Imanaka D; Kure T; Taniyama O; Toyodome A; Ijuin S; Sakae H; Sakurai K; Moriuchi A; Kanmura S; Ido A
PLoS One; 2020; 15(8):e0237475. PubMed ID: 32790728
[TBL] [Abstract][Full Text] [Related]
5. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong.
Chow VYS; Cheung WI
BMC Gastroenterol; 2024 Jan; 24(1):49. PubMed ID: 38273255
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
8. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
[TBL] [Abstract][Full Text] [Related]
9. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
10. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
[TBL] [Abstract][Full Text] [Related]
11. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
12. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
[TBL] [Abstract][Full Text] [Related]
13. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
14. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
[TBL] [Abstract][Full Text] [Related]
15. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
18. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
19. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
